Résumé
Background: Some people with substantial Alzheimer's disease pathology at autopsy had shown few characteristic clinical symptoms or signs of the disease, whereas others with little Alzheimer's disease pathology have been diagnosed with Alzheimer's dementia. We aimed to examine whether frailty, which is associated with both age and dementia, moderates the relationship between Alzheimer's disease pathology and Alzheimer's dementia. Methods: We did a cross-sectional analysis of data from participants of the Rush Memory and Aging Project, a clinical–pathological cohort study of older adults (older than 59 years) without known dementia at baseline, living in Illinois, USA. Participants in the cohort study underwent annual neuropsychological and clinical evaluations. In the present cross-sectional analysis, we included those participants who did not have any form of dementia or who had Alzheimer's dementia at the time of their last clinical assessment and who had died and for whom complete autopsy data were available. Alzheimer's disease pathology was quantified by a summary measure of neurofibrillary tangles and neuritic and diffuse plaques. Clinical diagnosis of Alzheimer's dementia was based on clinician consensus. Frailty was operationalised retrospectively using health variable information obtained at each clincial evaluation using the deficit accumulation approach (41-item frailty index). Logistic regression and moderation modelling were used to assess relationships between Alzheimer's disease pathology, frailty, and Alzheimer's dementia. All analyses were adjusted for age, sex, and education. Findings: Up to data cutoff (Jan 20, 2017), we included 456 participants (mean age at death 89·7 years [SD 6·1]; 316 [69%] women). 242 (53%) had a diagnosis of possible or probable Alzheimer's dementia at their last clinical assessment. Frailty (odds ratio 1·76, 95% CI 1·54–2·02; p<0·0001) and Alzheimer's disease pathology (4·81, 3·31–7·01; p<0·0001) were independently associated with Alzheimer's dementia, after adjusting for age, sex, and education. When frailty was added to the model for the relationship between Alzheimer's disease pathology and Alzheimer's dementia, model fit improved (p<0·0001). There was a significant interaction between frailty and Alzheimer's disease pathology (odds ratio 0·73, 95% CI 0·57–0·94; pinteraction=0·015). People with an increased frailty score had a weakened direct link between Alzheimer's disease pathology and Alzheimer's dementia; that is, people with a low amount of frailty were better able to tolerate Alzheimer's disease pathology, whereas those with higher amounts of frailty were more likely both to have more Alzheimer's disease pathology and for it to be expressed as dementia. Interpretation: The degree of frailty among people of the same age modifies the association between Alzheimer's disease pathology and Alzheimer's dementia. That frailty is related to both odds of Alzheimer's dementia and disease expression has implications for clinical management, since individuals with even a low level of Alzheimer's disease pathology might be at risk for dementia if they have high amounts of frailty. Further research should assess how frailty and cognition change over time to better elucidate this complex relationship. Funding: None.
Langue d'origine | English |
---|---|
Pages (de-à) | 177-184 |
Nombre de pages | 8 |
Journal | The Lancet Neurology |
Volume | 18 |
Numéro de publication | 2 |
DOI | |
Statut de publication | Published - févr. 2019 |
Note bibliographique
Funding Information:LMKW reports personal fees from DGI Clinical. MKA reports grants from GSK, Pfizer, and Sanofi. DAB reports grants from the National Institutes of Health (NIH). KR reports personal fees from Lundbeck. KR is President and Chief Science Officer of DGI Clinical, which has contracts with pharmaceutical companies on individualised outcome measurement. In 2017, KR attended an advisory board meeting with Lundbeck. Otherwise all personal fees are for invited guest lectures and academic symposia. KR is Associate Director of the Canadian Consortium on Neurodegeneration in Aging, which is funded by the Canadian Institutes of Health Research, with additional funding from the Alzheimer Society of Canada and several other charities, as well as from Pfizer Canada and Sanofi Canada. KR receives career support from the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research, and research support from the Nova Scotia Health Research Foundation, the Capital Health Research Fund and the Fountain Family Innovation Fund of the Nova Scotia Health Authority Foundation. OT and JG declare no competing interests.
Funding Information:
LMKW is supported by a biomedical doctoral fellowship from the Alzheimer's Society of Canada and the Canadian Institutes of Health Research (CIHR). MKA's work on frailty and dementia is part of a Canadian Consortium on Neurodegeneration in Aging (CCNA) investigation into how multi-morbidity modifies the risk of dementia and the patterns of disease expression (Team 14). The CCNA receives funding from the Canadian Institutes of Health Research ( CNA-137794 ) and partner organisations. KR's work on frailty and cognition is supported by CIHR PJT-156114 and by the Dalhousie Medical Research Foundation Kathryn Allen Weldon Chair of Alzheimer Disease Research. The MAP is supported by NIH grant R01AG17917 .
Publisher Copyright:
© 2019 Elsevier Ltd
ASJC Scopus Subject Areas
- Clinical Neurology